ALT Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Altimmune, Inc. had $0.0M of revenue in fiscal 2025, up 105.0% on the year before. Over five years, revenue changed β65.3% a year on average.
Last close Β· Oct 23, 2026
$2.12
2.3%Hi! I read Altimmune, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+105.0%
Yes. Sales grew 105.0% last year.
Does it make a profit?
β214,861.0%
No. It lost money last year.
Does profit turn into cash?
β164,746.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Altimmune, Inc. had $0.0M of revenue in fiscal 2025, up 105.0% on the year before. Over five years, revenue changed β65.3% a year on average. Its operating margin was β230,461.0%, up 285,399.0Β pts: of every 100 in sales, about β230,461 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Altimmune, Inc. lost $88.1M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$67.5M in fiscal 2025, β164,746.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.4M of shares on the open market and sold none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.4M
6 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Jerome Benedict DursoPresident and CEO, Director | Bought | 15,000 | $2.95 | $0.0M | Form 4 |
| Apr 6, 2026 | John GillDirector | Bought | 9,200 | $3.41 | $0.0M | Form 4 |
| Apr 1, 2026 | Gregory L WeaverChief Financial Officer | Bought | 10,000 | $3.15 | $0.0M | Form 4 |
| Apr 1, 2026 | Jerome Benedict DursoPresident and CEO, Director | Bought | 15,000 | $3.14 | $0.0M | Form 4 |
| Mar 6, 2026 | Gregory L WeaverChief Financial Officer | Bought | 5,000 | $3.54 | $0.0M | Form 4 |
| Mar 6, 2026 | Jerome Benedict DursoPresident and CEO, Director | Bought | 20,000 | $3.54 | $0.1M | Form 4 |
| Jan 8, 2026 | Wayne PisanoDirector | Bought | 5,000 | $4.08 | $0.0M | Form 4 |
| Jan 5, 2026 | Catherine A. SohnDirector | Bought | 500 | $4.24 | $0.0M | Form 4 |
| Dec 29, 2025 | Diane JorkaskyDirector | Bought | 527 | $3.80 | $0.0M | Form 4 |
| Dec 23, 2025 | John GillDirector | Bought | 12,500 | $4.10 | $0.1M | Form 4 |
| Dec 22, 2025 | Jerome Benedict DursoDirector | Bought | 12,500 | $4.13 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Altimmune, Inc. has $239M more cash than debt.
Cash, debt and the ratios that show how comfortably Altimmune, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $190M | $185M | $198M | $132M | $273M |
| Debt incl. finance leases | $1.5M | $4.6M | β | β | $34.3M |
| Debt / equity | 0.0x | 0.0x | β | β | 0.2x |
| Interest coverage | β19,382.8x | β10,967.5x | β2,740.8x | β11,463.6x | β57.8x |
| Current ratio | 11.2x | 11.3x | 17.3x | 13.1x | 18.5x |
| Quick ratio | 11.2x | 11.3x | 17.3x | 13.1x | 18.5x |
| Total assets | $219M | $207M | $211M | $139M | $280M |
| Total liabilities | $19.7M | $21.6M | $16.5M | $15.8M | $55.0M |
| Shareholders' equity | $199M | $185M | $194M | $124M | $225M |
| Net debt (β = net cash) | β$189M | β$180M | β | β | β$239M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Altimmune, Inc. passes 4 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 8 | 4 / 8 | 3 / 8 | 4 / 8 | 2 / 8 | 3 / 8 | 3 / 7 | 1 / 7 | 4 / 7 |
| Accruals ratio | β12.3% | β51.7% | β50.6% | β20.1% | β9.9% | β8.1% | β10.4% | β6.1% | β8.7% | β9.8% |
| Altman Z'' | 0.70 | β4.64 | β0.16 | β1.05 | 14.19 | 8.83 | 5.76 | 8.19 | β3.94 | 0.63 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.2M | $10.7M | $10.3M | $5.8M | $8.2M | $4.4M | β$0.1M | $0.4M | $0.0M | $0.0M |
| Net interest income | $0.2M | β | β | β | β | β | β | β | β | β |
| Research and development | $7.2M | $18.4M | $18.5M | $17.8M | $49.8M | $74.5M | $70.5M | $65.8M | $82.2M | $66.4M |
| Operating income | β$11.1M | β$52.0M | β$42.8M | β$21.5M | β$54.8M | β$96.9M | β$87.7M | β$95.9M | β$103M | β$94.5M |
| Interest expense | $0.0M | $0.2M | $0.3M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $1.6M |
| Pretax income | β$11.1M | β$52.1M | β$45.3M | β$20.6M | β$54.5M | β$97.1M | β$84.9M | β$88.4M | β$95.1M | β$88.8M |
| Income tax | $0.0M | β$5.6M | β$6.1M | β$0.1M | β$5.4M | β | β$0.2M | β | β | β$0.7M |
| Net income | β$11.1M | β$46.4M | β$39.2M | β$20.5M | β$49.0M | β$97.1M | β$84.7M | β$88.4M | β$95.1M | β$88.1M |
| Net income to common | β$11.5M | β$51.4M | β$42.5M | β$21.0M | β$49.0M | β | β | β | β | β |
| Diluted EPS | $2.95 | β$118.91 | β$15.16 | β$1.60 | β$1.91 | β$2.35 | β$1.81 | β$1.66 | β$1.34 | β$1.00 |
| Diluted shares | 0.07B | 0.00B | 0.00B | 0.01B | 0.03B | 0.04B | 0.05B | 0.05B | 0.07B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | β$6.4M | β$20.2M | β$9.4M | β$9.6M | β$34.3M | β$78.2M | β$62.6M | β$75.8M | β$79.8M | β$67.5M |
| Capital expenditure | $0.1M | $0.1M | $1.0M | $0.0M | $0.2M | $12.1M | $0.1M | $0.0M | β | $0.0M |
| Free cash flow | β$6.5M | β$20.3M | β$10.4M | β$9.6M | β$34.5M | β$90.4M | β$62.7M | β$75.9M | β | β$67.5M |
| Depreciation and amortization | $0.1M | $0.1M | $0.2M | $0.4M | $0.4M | $0.6M | β$0.2M | $0.5M | $0.2M | $0.1M |
| Stock-based compensation | $1.0M | $1.4M | $0.8M | $1.3M | $2.6M | $5.5M | $8.1M | $10.6M | $14.4M | $16.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $69.7M | $8.8M | $33.7M | $37.2M | $216M | $190M | $185M | $198M | $132M | $273M |
| Total debt | $0.5M | $0.6M | $0.6M | $1.9M | $1.8M | $1.5M | $4.6M | β | β | $34.3M |
| Current assets | $4.5M | $23.5M | $39.4M | $39.4M | $230M | $204M | $193M | $210M | $137M | $278M |
| Current liabilities | $5.5M | $3.8M | $4.5M | $3.9M | $12.0M | $18.3M | $17.1M | $12.1M | $10.5M | $15.0M |
| Property and equipment, net | $0.2M | $0.6M | $1.3M | $1.1M | $1.1M | $1.4M | $1.1M | $0.7M | $0.4M | $0.3M |
| Goodwill | $18.8M | β | $0.0M | $0.0M | β | β | β | β | β | β |
| Intangible assets | $15.0M | $38.7M | $13.9M | $12.7M | $12.8M | $12.4M | $12.4M | $0.0M | $0.0M | β |
| Total assets | $38.4M | $63.0M | $54.8M | $54.1M | $245M | $219M | $207M | $211M | $139M | $280M |
| Total liabilities | $6.2M | $14.4M | $6.4M | $8.5M | $19.2M | $19.7M | $21.6M | $16.5M | $15.8M | $55.0M |
| Shareholders' equity | $32.2M | $39.4M | $48.3M | $45.5M | $226M | $199M | $185M | $194M | $124M | $225M |
| Margins | ||||||||||
| Operating margin | β342.7% | β484.7% | β414.6% | β370.0% | β669.5% | β2,197.6% | 129,029.4% | β22,518.5% | β515,860.0% | β230,461.0% |
| EBITDA margin | β340.8% | β483.9% | β412.5% | β363.3% | β664.3% | β2,185.1% | 129,330.9% | β22,406.6% | β514,670.0% | β230,187.8% |
| Net margin | β342.6% | β432.3% | β379.2% | β353.7% | β599.2% | β2,201.6% | 124,577.9% | β20,762.2% | β475,295.0% | β214,861.0% |
| FCF margin | β200.2% | β189.3% | β100.3% | β165.5% | β421.6% | β2,048.9% | 92,223.5% | β17,806.8% | β | β164,746.3% |
| Net interest share of revenue | 5.2% | β | β | β | β | β | β | β | β | β |
| Returns | ||||||||||
| Return on capital | β | β131.7% | β223.1% | β167.2% | β367.5% | β744.2% | β1,388.0% | β | β | β |
| Return on capital employed | β33.7% | β87.9% | β85.3% | β42.8% | β23.5% | β48.3% | β46.2% | β48.3% | β80.1% | β35.7% |
| Return on equity | β34.4% | β129.7% | β89.3% | β43.7% | β36.1% | β45.7% | β44.1% | β46.6% | β59.9% | β50.6% |
| Return on assets | β28.9% | β91.5% | β66.5% | β37.7% | β32.8% | β41.9% | β39.8% | β42.4% | β54.3% | β42.0% |
| Return on tangible equity | β | β7,625.2% | β123.3% | β64.0% | β23.0% | β52.0% | β49.0% | β45.6% | β77.0% | β39.2% |
| Growth | ||||||||||
| Revenue growth | β | 231.8% | β3.8% | β43.8% | 41.1% | β46.1% | β101.5% | β | β95.3% | 105.0% |
| EPS growth | β | β4,130.8% | β | β | β | β | β | β | β | β |
| Share count change | β | β99.3% | 548.9% | 368.3% | 95.3% | 61.0% | 13.7% | 13.5% | 33.3% | 24.1% |
| Financial health | ||||||||||
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | β | β | 0.2x |
| Interest coverage | β288.1x | β321.1x | β144.2x | β9,756.8x | β5,829.6x | β19,382.8x | β10,967.5x | β2,740.8x | β11,463.6x | β57.8x |
| Current ratio | 0.8x | 6.1x | 8.7x | 10.0x | 19.2x | 11.2x | 11.3x | 17.3x | 13.1x | 18.5x |
| Quick ratio | 0.8x | 6.1x | 8.7x | 10.0x | 19.2x | 11.2x | 11.3x | 17.3x | 13.1x | 18.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.9% | 1.0% | 9.4% | 0.0% | 2.5% | 274.8% | β185.3% | 11.0% | β | 26.8% |
| Stock comp / revenue | 29.8% | 13.4% | 7.5% | 21.8% | 31.5% | 125.1% | β11,913.2% | 2,497.7% | 71,965.0% | 39,209.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 4.0 | 3.0 | 4.0 | 2.0 | 3.0 | 3.0 | 1.0 | 4.0 |
| Altman Z'' | 0.7 | β4.6 | β0.2 | β1.1 | 14.2 | 8.8 | 5.8 | 8.2 | β3.9 | 0.6 |
| Accruals ratio | β12.3% | β51.7% | β50.6% | β20.1% | β9.9% | β8.1% | β10.4% | β6.1% | β8.7% | β9.8% |
Source: SEC EDGAR XBRL filings (CIK 0001326190). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
